Sell Apollo Hospitals Enterprise Ltd For Target Rs.3,030 - Yes Securities
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Hospitals shine but pricing elevated
Our view
Apollo has surprised with solid delivery in the core hospitals business especially on the ARPOB (realizations/bed) which drove recovery in mature hospitals margin. Management indicated it expects ARPOB to sustain even as sensitivity to change in ARPOB is quite meaningful. Factoring such elevated ARPOB would imply assuming case mix remains similar to what it has been during the pandemic. We refrain from making such an overarching change in realization/bed assumption particularly as revival in footfalls would tend to reduce the share of high end surgeries. Pharmacy business carried 24/7 operating costs of Rs845mn in H1 FY22 with online blended discount of ~12%; any rise in discounting is likely to cramp segment margin. Given the sharp rise in ARPOB in H1, we raise realization estimates resulting in ~40% rise in FY22 EPS (Ex‐ exceptional gain) though FY23/24 estimates undergo a relatively modest change. Given the near term strength in ARPOB, raise EV/EBIDTA multiple for hospital business to 13x but retain SELL with revised TP Rs3,030 (earlier Rs2,750).
Result Highlights
* Revenue down by 1% QoQ vs our estimate of ‐10% QoQ.
* Company announced acquisition of majority stake in Excelcare Hospitals in Guwahati having 180 bed capacity indicating strong focus in North East market at an EV of Rs2.1bn
* Gross margin increased by 446bps QoQ to 49.6% and EBITDA margins were also up 272bps. Increase due to reduced Covid related revenues/exp sequentially and a larger share of high end surgeries
Valuations
Given the sharp rise in ARPOB in H1, we raise realization estimates resulting in ~40% rise in FY22 EPS (Ex‐exceptional gain) though FY23/24 estimates undergo a relatively modest change. Given the near term strength in ARPOB, raise EV/EBIDTA multiple for hospital business to 13x but retain SELL with revised TP Rs3,030 (earlier Rs2,750).
To Read Complete Report & Disclaimer Click Here
Please refer disclaimer at https://yesinvest.in/privacy_policy_disclaimers
SEBI Registration number is INZ000185632
Above views are of the author and not of the website kindly read disclaimer
